After grabbing 3508.0 shares, the institutional investor is now in possession of 3508.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.29% having worth around $11261.0. Moreover, Wealth Enhancement Advisory Servi increased its share by 2133.0 to have a control over 2133.0 shares.
Vivos Therapeutics Inc (VVOS) concluded trading on 11/29/23 at a closing price of $41.00, with 46.44 million shares of worth about $1.9 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 329.77% during that period and on Wednesday the price saw a gain of about 833.94%. Currently the company’s common shares owned by public are about 1.20M shares, out of which, 1.00M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the VVOS stock and their offered price forecasts bring an average price target of $6.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $6.00 and could fall to a lowest price of $6.00. The stock’s current price level is -583.33% below of average price target set by the analysts, while a dip to estimated low would result in loss of -583.33% for the stock. However, touching the estimated high of $6.00 would mean a loss of -583.33% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Nasdaq Composite Index F are the top 3 mutual funds which are holding stakes in Vivos Therapeutics Inc Vanguard Extended Market Index Fu is currently holding 10477.0 shares of worth totaling $33631.0. The company recently came buying 0.0 shares which brought its stake up to 0.88% of the company’s outstanding shares. Fidelity Nasdaq Composite Index F, after buying 1458.0 shares, have now control over 0.12% of the stake in the company. It holds 0.0 shares of worth $4680.0.
Vivos Therapeutics Inc (NASDAQ: VVOS) started trading at $11.93, above $7.54 from concluding price of the previous day. However, the stock later moved at a day high price of 48.79, or with a gain of 833.94%. Stock saw a price change of 781.72% in past 5 days and over the past one month there was a price change of 970.50%. Year-to-date (YTD), VVOS shares are showing a performance of 307.96% which increased to 182.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.73 but also hit the highest price of $74.05 during that period. The average intraday trading volume for Vivos Therapeutics Inc shares is 204.84K. The stock is currently trading 1000.25% above its 20-day simple moving average (SMA20), while that difference is up 681.48% for SMA50 and it goes to 377.75% higher than SMA200.
HRT Financial LLC acquired 3508.0 shares of Vivos Therapeutics Inc having value of about $11261.0. Vivos Therapeutics Inc (NASDAQ: VVOS) currently have 1.20M outstanding shares and institutions hold larger chunk of about 14.95% of that. Holding of mutual funds in the company is about 1.62% while other institutional holders and individual stake holders have control over 13.34% and — of the stake respectively.
The stock has a current market capitalization of $49.20M and its 3Y-monthly beta is at 2.92. It has posted earnings per share of -$14.70 in the same period. It has Quick Ratio of 0.28 while making debt-to-equity ratio of 42.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VVOS, volatility over the week remained 90.42% while standing at 31.75% over the month.
Analysts are in expectations that Vivos Therapeutics Inc (VVOS) stock would likely to be making an EPS of -$2.06 in the current quarter, while forecast for next quarter EPS is -$1.53 and it is -$4.62 for next year. For the current quarter EPS, analysts have given the company a lowest target -$2.06 which is -$2.06 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 55.85% while it is estimated to increase by 59.76% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Vivos Therapeutics Inc (VVOS)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
